Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Stock analysts at Atb Cap Markets decreased their FY2024 EPS estimates for Bradmer Pharmaceuticals in a research report issued to clients and investors on Sunday, January 26th. Atb Cap Markets analyst M. Toner now anticipates that the company will earn $3.01 per share for the year, down from their previous forecast of $3.63. Atb Cap Markets also issued estimates for Bradmer Pharmaceuticals’ FY2025 earnings at $1.51 EPS.
Separately, HC Wainwright upgraded shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, October 10th.
Bradmer Pharmaceuticals Stock Performance
Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported C($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of C($0.52) by C$0.34.
Read More
- Five stocks we like better than Bradmer Pharmaceuticals
- Roth IRA Calculator: Calculate Your Potential Returns
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- 3 Dividend Kings To Consider
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
